Low-Intensity Extracorporeal Shock Wave Therapy Restores Passive Urethral Closure Mechanism in Vaginal Distension Rat Model Authors: Takahiro Akimoto, Asuka Ashikari, Masahiro Kurobe, Gakuya Takamatsu, Yoshiyuki Akiyama, Haruki Kume, Minoru Miyazato Published: 2026 ABSTRACT AbstractIntroduction and HypothesisLow-intensity extracorporeal shock wave therapy (LiESWT) is a promising noninvasive therapy for stress urinary incontinence (SUI). We assessed whether LiESWT restores urethral function in a vaginal distension (VD)-induced rat model of SUI, focusing on pelvic floor tissue remodeling and endoplasmic reticulum stress pathway as potential mechanisms.MethodsEighty-one female Sprague–Dawley rats underwent functional and tissue analyses. Sneezing was induced to assess urethral pressure responses. Leak point pressure (LPP) was measured with or without hypogastric and pudendal nerve transections. Tissue remodeling and molecular pathways were assessed using histological and molecular expression analyses.ResultsIn VD rats, baseline urethral pressure (9.9 ± 4.3 vs 17.6 ± 3.1 cmH2O) and LPP (27.4 ± 4.7 vs 37.0 ± 7.0 cmH2O) were lower than in normal rats (both p < 0.05). LiESWT restored the baseline urethral pressure (16.3 ± 4.7 cmH2O) and LPP (37.5 ± 4.9 cmH2O) in VD rats (p < 0.05). Notably, LPP enhancement persisted after bilateral hypogastric and pudendal nerve transections. Additionally, LiESWT tended to reduce VD-induced vaginal smooth muscle fibrosis histologically, whereas collagen type I alpha and elastin mRNA expression remained elevated in both groups. Western blotting revealed no sustained activation of protein kinase R-like endoplasmic reticulum kinase (PERK) at 96 h after the final LiESWT.ConclusionsLiESWT enhanced urethral function in the VD-induced SUI model by potentially facilitating pelvic floor tissue remodeling, thereby restoring passive urethral closure. The absence of sustained PERK activation in the late phase indicates the safety of LiESWT for SUI.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s00192-026-06703-7.Keywords: Endoplasmic reticulum stress, Leak point pressure, Low-intensity extracorporeal shockwave therapy, Stress urinary incontinence, Vaginal distension Introduction Stress urinary incontinence (SUI) affects quality of life, specifically in postmenopausal women [1]. Noninvasive treatments, such as pelvic floor muscle training, are available [2]. However, they require a prolonged time to achieve effects and exhibit variable success rates [2]. Additionally, although pharmacological therapies, such as clenbuterol are available, they exhibit limited efficacy [3]. For severe cases, surgical treatment with mesh implantation is effective but highly invasive. Moreover, mesh-related complications have resulted in Food and Drug Administration warnings and updated guidelines [4]. Therefore, developing novel minimally invasive therapies is urgently needed. Understanding the pathophysiology of SUI is essential for developing such minimally invasive therapies. Urethral hypermobility and intrinsic sphincter deficiency are the two major contributors to SUI, with the latter being the dominant mechanism [5, 6]. Current treatments primarily provide mechanical urethral support and fail to address the underlying pathophysiology. Vaginal structural deterioration contributes to both reduced urethral pressure and excessive mobility [7–10]. Therefore, restoring the pelvic tissue structure and function may be crucial for enhancing SUI outcomes. In this context, low-intensity extracorporeal shock wave therapy (LiESWT) has attracted attention as a potential therapeutic approach to facilitate tissue restoration. LiESWT facilitates angiogenesis [11], reduces fibrosis [12], and enhances nerve regeneration [13] in damaged tissue. LiESWT enhances urinary function in various rat models, including lipopolysaccharide-induced cystitis [14], spinal cord injury [12], and maternal separation stress [15]. Additionally, it benefits SUI by facilitating tissue regeneration in both animal models and clinical trials [13, 16, 17]. LiESWT activates the protein kinase R-like endoplasmic reticulum kinase (PERK)/activating transcription factor 4 (ATF4) signaling pathway in cavernous tissues [18]. This pathway is the primary mediator of the endoplasmic reticulum (ER) stress response, and its activation is associated with enhanced brain-derived neurotrophic factor (BDNF) expression [18]. However, sustained PERK activation can facilitate apoptosis and impair tissue repair [19]. Whether LiESWT induces transient beneficial ER stress responses or sustained harmful activation in the urogenital tissues remains unclear. To address this question, we utilized the vaginal distension (VD) model, which simulates the mechanical stress and ischemia experienced by vaginal tissues during pregnancy and vaginal delivery and is widely used to study SUI [20–22]. Two distinct mechanisms contribute to urinary continence during increased abdominal pressure. The passive mechanism maintains baseline urethral pressure through smooth muscle tone and periurethral tissue support [6]. In contrast, the active mechanism involves the contraction of rapid external urethral sphincter and pelvic floor striated muscle via the somatic nerve [5]. Both mechanisms are impaired in VD rats [23, 24]. We previously established a rat model that enables the measurement of sneeze-induced urethral closure mechanisms [23]. In the VD model, LiESWT enhances leak point pressure (LPP) and facilitates tissue repair [22]. However, it remains unclear whether LiESWT enhances continence during stress events, such as sneezing through passive, active, or both mechanisms. Therefore, in this study, we assessed the effects of LiESWT on urethral function using sneezing-induced urethral pressure measurements and LPP assessments. Additionally, we examined tissue remodeling and ER stress-related gene expression in vaginal and urethral tissues to assess the mechanisms underlying functional recovery in the VD rat model. Materials and Methods Animals Eighty-one female Sprague–Dawley rats (9-weeks-old) were used. This study was approved by the Institutional Animal Care and Use Committee of our institution and adhered to the ARRIVE guidelines (approval no. A2021041). Vaginal Distension (VD) The rats were anesthetized with 2% isoflurane. Ketamine (80 mg/kg) and xylazine (10 mg/kg) were administered intraperitoneally [23]. After 15 min, adequate sedation was confirmed by the absence of a withdrawal reflex to tail-pinching. A lubricated 10-Fr balloon catheter was inserted into the vagina and secured with a 4–0 suture. The balloon was inflated with 4 mL distilled water. VD was maintained for 3 h, with catheter position monitored throughout the procedure. LiESWT Protocol Under 2% isoflurane anesthesia, LiESWT (0.12 mJ/mm2, 2 Hz, 300 shocks/session) was delivered transperineally using an ED-1000® device (Medispec, Yehud, Israel). The transducer was adjusted to an optimal focal depth to target the mid-urethral region. Treatment was performed 24 and 72 h post-VD (Fig. 1a). A gel pad was used as a standoff to ensure proper focal zone alignment (Fig. 1b). Experimental setup for low-intensity extracorporeal shock wave therapy (LiESWT). (a) Experimental timeline. Vaginal distension (VD) was performed on day 0, followed by LiESWT on days 1 and 3. Urethral pressure (UP), leak point pressure (LPP), and tissue harvest for histology, western blotting (WB), and polymerase chain reaction (PCR) were performed on day 7. (b) Schematic illustration of the LiESWT protocol. The transducer was positioned on the perineum with coupling gel to ensure proper focal zone alignment (focal distance 6 cm). Shock waves (0.12 mJ/mm2, 2 Hz, 300 shocks/session) were directed toward the urethra and vagina Urodynamic Measurements Sneeze-Induced Microtip Urethral Measurement Twenty-four rats (8 normal and 16 VD rats, including those from experiment 1) were used for this experiment. The rats were anesthetized with 2% isoflurane. A PE-10 catheter was placed in the jugular vein for urethane administration. Both ureters were ligated. Bilateral pelvic nerves were transected to prevent bladder contractions and reduce interference from the natural voiding reflexes. Fecal material was removed from the rectum. A homemade balloon catheter (1 cm diameter) was inserted transrectally into the abdominal cavity and connected to a pressure transducer to record abdominal pressure during sneezing. Isoflurane anesthesia was discontinued after surgery. Urethane (0.5 g/kg) was administered intraperitoneally, with additional intravenous doses (2.5 mg increments) administered as needed—total dose ranging from 1.0 to 1.2 g/kg. An appropriate depth of anesthesia was maintained to preserve reflex responses while ensuring animal welfare. A 3.5-Fr microtip catheter with a side-mounted transducer (SPR-524; Millar Instruments, Houston, TX) was inserted into the mid-urethra. The catheter was positioned approximately 12.5 mm from the urethral orifice. Optimal positioning was confirmed by the urethral pressure profile. Sneezing was induced by gentle mechanical stimulation of the nostril using trimmed rat whiskers [23]. Sixteen consecutive sneezes were collected at 30-s intervals. The baseline urethral pressure, peak urethral pressure during sneezing, and simultaneous abdominal pressure were recorded continuously. Active urethral response (AUR) during sneezing was defined as the difference between the maximum urethral pressure (MUP) and baseline urethral pressure. Data acquisition was performed using a PowerLab system. Sneezes with pressure responses outside ± 2 standard deviation (SD) were excluded. Additionally, sneezes below 3 cmH2O were excluded from the analysis. Leak Point Pressure (LPP) Measurement Thirty rats (10 normal, 10 VD, and 10 VD + LiESWT) were used exclusively for this experiment. The rats were anesthetized with 2% isoflurane. The bilateral pelvic nerves were transected through an abdominal incision. A vesicostomy was created by inserting a PE-50 catheter through the bladder dome. Urethane (1.2 g/kg) was administered subcutaneously before wound closure. After 2 h of stabilization, the rats were positioned vertically. The bladder was filled with saline containing Evans blue (100 μg/mL) through a vesicostomy catheter connected to a syringe without a plunger. The syringe fluid level was set at the bladder level as a zero reference point. Intravesical pressure was monitored continuously. The saline reservoir was gradually increased until visible urine leakage occurred from the urethral meatus. LPP was recorded as the height difference (cmH2O) between the bladder and fluid level at leakage onset. Three measurements were averaged per rat. The bladder was emptied after each measurement. Following the initial LPP measurements, the bilateral hypogastric and pudendal nerves were transected under the same anesthesia to distinguish the contribution of passive urethral closure mechanisms from that of neural tone. After a 2-h stabilization period, LPP measurements were repeated using the same protocol. Histological Analysis The bladder, urethra, and vagina were excised en bloc, fixed in 10% formalin for up to 24 h, and embedded in paraffin. Sagittal sections (4 µm thick) were stained with Masson’s trichrome. For each sample, three random fields were captured at 400 × magnification in three regions surrounding the external urethral sphincter—vaginal smooth muscle, urethral smooth muscle, and external urethral sphincter (striated muscle). Collagen (blue) and muscle (red) areas were quantified using the ImageJ software (National Institutes of Health). Red, green, and blue channels were separated, and color thresholding was used to identify the collagen and muscle regions. The fibrosis ratio was calculated as collagen area/(collagen + muscle area). Western Blot Analysis Protein Isolation and Western Blot Analysis In separate groups of rats (normal, n = 3; VD, n = 4; and VD + LiESWT, n = 4), vaginal and urethral tissue samples were harvested for protein analysis. These animals did not undergo LPP or sneeze tests to avoid the effects of repeated mechanical stress on protein expression levels. Tissue samples were immediately placed in radioimmunoprecipitation assay buffer containing 1% Triton X-100, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate, supplemented with protease and phosphatase inhibitors (β-glycerophosphate, sodium orthovanadate, and sodium fluoride), and manually homogenized. The samples were further homogenized using an ultrasonic homogenizer and centrifuged (12,000 rpm, 10 min, 4 °C). The supernatant was collected for analyses. Proteins were separated via sodium dodecyl sulfate–polyacrylamide gel electrophoresis (6% for PERK and 10% for β-actin) and transferred onto nitrocellulose membranes. The membranes were blocked using Blocking One (Nacalai Tesque). The primary antibodies used were anti-PERK (C33E10, 1:1500, rabbit monoclonal; Cell Signaling Technology) and anti-β-actin (MAB1501, 1:8000, mouse monoclonal; Merck). Secondary antibodies were anti-rabbit IgG-horseradish peroxidase (HRP) (A0545, 1:5000, goat polyclonal; Sigma-Aldrich) for PERK and anti-mouse IgG-HRP (AP160P, 1:5000, rabbit polyclonal; Millipore) for β-actin. Because of the lack of reactivity with phospho-specific PERK antibody even in positive controls, PERK phosphorylation was assessed using total PERK antibody through electrophoretic mobility shift. Protein bands were detected using Chemi-Lumi One Ultra (Nacalai Tesque) for PERK and ECL Prime Western Blotting Detection Reagent (Cytiva) for β-actin. Real-Time Polymerase Chain Reaction (PCR) Analysis RNA Extraction In additional separate groups of rats (n = 5 per group), vaginal and urethral tissue samples were harvested for mRNA analyses. These animals did not undergo LPP or sneeze tests to avoid the effects of repeated mechanical stress on transcript expression levels. Tissue samples were immediately placed in 1.5 mL tubes and snap-frozen in liquid nitrogen. Total RNA was extracted from the frozen tissue using TRIzol reagent (Invitrogen), homogenized, purified using the NucleoSpin RNA kit (Macherey–Nagel, Germany), and stored at −80 °C. Complementary DNA (cDNA) Synthesis Before cDNA synthesis, RNA quality was assessed via electrophoresis on 1.0% agarose gels with 500 bp markers. RNA concentration and purity were determined using spectrophotometry. cDNA was synthesized from 2 µg of total RNA (maximum 10 µL for samples < 200 ng/µL) using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) in a 20 µL reaction volume. Reverse transcription was performed at 25 °C for 10 min, 37 °C for 120 min, and 85 °C for 5 min, followed by incubation at 4 °C. Quantitative Real-Time PCR (RT-qPCR) RT-qPCR was performed using the StepOnePlus Real-Time PCR System (Applied Biosystems) with TB Green® Premix Ex Taq™ II (Takara Bio) following the manufacturer’s protocol to analyze gene expression associated with extracellular matrix remodeling, muscle differentiation, hypoxia response, fibrosis, ER stress, growth factor signaling, and cellular senescence. The analyzed genes, primer sequences, and their original references are listed in Supplementary Table 1. Thermal cycling conditions were as follows: initial denaturation at 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s, 55 °C for 1 min, and 72 °C for 30 s. All samples were run in duplicate. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal reference gene after confirming stable expression across experimental conditions. Preliminary experiments confirmed that the amplification efficiencies of all target genes were comparable to that of GAPDH. Relative gene expression was calculated using the standard curve method. Statistical Analysis Data are presented as the mean ± SD or median (interquartile range), as appropriate. Normality of distribution was assessed using the Shapiro–Wilk test. For normally distributed data, the homogeneity of variance was assessed using the Bartlett’s test. Data meeting both assumptions were analyzed using one-way analysis of variance followed by the Tukey–Kramer honestly significant difference test. Nonparametric data or data with unequal variances were analyzed using the Kruskal–Wallis test, followed by the Steel–Dwass test. Statistical significance was set at p < 0.05. Statistical analyses were performed using JMP Student’s Edition (version 19; JMP Statistical Discovery LLC, Cary, NC, USA). Graphs were created using GraphPad Prism (version 8; GraphPad Software, San Diego, CA, USA). Results Urodynamic Findings Baseline urethral pressure was significantly lower in VD rats (9.9 ± 4.3 cmH2O) than that in normal controls (17.6 ± 3.1 cmH2O, p < 0.05). LiESWT restored baseline pressure to levels comparable to those in normal controls (16.3 ± 4.7 cmH2O) (Table 1). MUP did not differ significantly between the VD and LiESWT groups (p = 0.157). Because baseline pressure was restored while AUR remained significantly impaired in both the VD (4.8 [2.0–7.2] cmH2O) and LiESWT groups (4.3 [2.7–6.5] cmH2O) compared with that in normal controls (44.4 [31.9–54.5] cmH2O, p < 0.05), the modest numerical increase in MUP in the LiESWT group was largely attributable to baseline pressure recovery. These findings indicate that LiESWT primarily restores baseline urethral tone rather than dynamic contractile responses to sneezing stimuli. Table 1Sneezing experimentNormalVDLiESWTUrethral baseline pressure (BP)17.6 ± 3.19.9 ± 4.3*16.3 ± 4.7♰Maximum urethral pressure (MUP)62.1 [47.6–70.0]16.0 [10.1–18.4]*22.1 [15.5–28.4]ΨActive urethral response (AUR)44.4 [31.9–54.5]4.8 [2.0–7.2]*4.3 [2.7–6.5]ΨAbdominal pressure (AP)8.2 ± 1.29.3 ± 2.510.1 ± 2.1AUR/AP ratio5.8 [4.1–7.6]0.4 [0.2–0.9]*0.5 [0.4–0.9]ΨData are presented as mean ± standard deviation (SD) for normally distributed variables and median [interquartile range] for non-normally distributed variables. For normally distributed data, one-way analysis of variance (ANOVA) followed by the Tukey–Kramer honestly significant difference test was used. For non-normally distributed data, the Kruskal–Wallis test followed by the Steel–Dwass test was usedVD vaginal distension; LiESWT low-intensity extracorporeal shock wave therapy* Normal vs VD p < 0.05, ♰ VD vs LiESWT p < 0.05, Ψ Normal vs LiESWT p < 0.05 Sneezing experiment Data are presented as mean ± standard deviation (SD) for normally distributed variables and median [interquartile range] for non-normally distributed variables. For normally distributed data, one-way analysis of variance (ANOVA) followed by the Tukey–Kramer honestly significant difference test was used. For non-normally distributed data, the Kruskal–Wallis test followed by the Steel–Dwass test was used VD vaginal distension; LiESWT low-intensity extracorporeal shock wave therapy * Normal vs VD p < 0.05, ♰ VD vs LiESWT p < 0.05, Ψ Normal vs LiESWT p < 0.05 LPP measurements obtained with intact hypogastric and pudendal nerves exhibited significant differences among the groups (Table 2). Control rats maintained LPP at 37.0 ± 7.0 cmH2O. VD reduced LPP to 27.4 ± 4.7 cmH2O. LiESWT enhanced LPP to 37.5 ± 4.9 cmH2O, fully restoring it to control levels. After transection of the hypogastric and pudendal nerves, the protective effect of LiESWT was preserved. LiESWT-treated rats exhibited significantly higher LPP (31.0 ± 5.8 cmH2O) than that of VD rats (20.2 ± 2.8 cmH2O, p < 0.05), demonstrating that therapeutic benefit persists despite transection of pelvic, hypogastric, and pudendal nerves (Table 2). Table 2Leak point pressure measurementsNormalVDLiESWTLPP37.0 ± 7.027.4 ± 4.7*37.5 ± 4.9♰LPP after hypogastric and pudendal nerve transection27.3 ± 3.920.2 ± 2.831.0 ± 5.8♰Data are presented as mean ± standard deviation (SD). Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison testVD vaginal distension; LiESWT low-intensity extracorporeal shock wave therapy; LPP leak point pressure* Normal vs VD p < 0.05, ♰ VD vs LiESWT p < 0.05 Leak point pressure measurements Data are presented as mean ± standard deviation (SD). Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test VD vaginal distension; LiESWT low-intensity extracorporeal shock wave therapy; LPP leak point pressure * Normal vs VD p < 0.05, ♰ VD vs LiESWT p < 0.05 Histological Findings Quantitative histological analysis revealed that the fibrosis ratio in vaginal smooth muscle layers tended to be higher in VD rats (37.1 ± 4.5%) than that in normal controls (29.1 ± 5.9%, p = 0.077). The fibrosis ratio in LiESWT-treated rats (28.4 ± 5.3%) tended to be lower than that of VD alone (p = 0.055), with no significant difference observed between LiESWT-treated and normal rats (p = 0.979) (Fig. 2j). In contrast, no significant differences were observed in urethral smooth muscle or external urethral sphincter among the groups (Fig. 2k, l). These findings indicate that LiESWT predominantly affects remodeling of the extracellular matrix in the vaginal wall tissue. Qualitatively, microvascular congestions were noted in the urethral tissue of VD rats (Fig. 2e, asterisks). Histological analysis of vaginal and urethral tissues. Representative images of Masson’s trichrome staining (blue collagen, red muscle fibers). (a–c) Sagittal sections of urethral and vaginal tissues at 40 × magnification (upper urethra, lower vagina; right cranial, left caudal): (a) Normal, (b) Vaginal distension (VD), (c) VD + low-intensity extracorporeal shock wave therapy (LiESWT). (d–f) Urethral smooth muscle at 400 × magnification: (d) Normal, (e) VD, (f) VD + LiESWT. (g–i) Vaginal smooth muscle at 400 × magnification: (g) Normal, (H) VD, (I) VD + LiESWT. Asterisks indicate microvascular changes in VD rats (e). Scale bars = 300 µm (a–c) and 30 µm (d–i). (j–l) Quantitative analysis of fibrosis ratio (collagen area/[collagen + muscle area]): (j) vaginal smooth muscle, (k) urethral smooth muscle, (l) external urethral sphincter (striated muscle). Data are presented as mean ± standard deviation (SD) (n = 5 per group). One-way analysis of variance followed by the Tukey–Kramer honestly significant difference test Western Blot Findings PERK expression was analyzed in urethral and vaginal tissues from all three groups. A single band at approximately 140 kDa was detected in all groups (normal, VD, and LiESWT), with no band shift indicative of PERK phosphorylation (Fig. 3). The mobility shift assay was confirmed using λ protein phosphatase treatment that eliminated the upper shifted band in the positive control samples (Supplementary Fig. 1). These results indicate that PERK phosphorylation was not sustained 96 h after the final LiESWT session. Western blot analysis of protein kinase R-like endoplasmic reticulum kinase (PERK) expression. Representative western blot images showing PERK (~ 140 kDa) and β-actin expression in urethral and vaginal tissues from normal (n = 3), vaginal distension (VD) (n = 4), and VD + low-intensity extracorporeal shock wave therapy (LiESWT) (n = 4) groups at 96 h after the final LiESWT session. Only a single band at approximately 140 kDa was detected in all groups, with no evidence of band shift indicating PERK phosphorylation. β-actin levels were consistent across all samples Quantitative Real-Time PCR (RT-qPCR) Findings The mRNA expression levels in the vaginal tissue are illustrated in Fig. 4. Collagen type I alpha chain (Col1a) was significantly higher in VD rats than that in normal controls (p < 0.05) (Fig. 4a). LiESWT-treated rats exhibited intermediate levels that were not significantly different from either the normal or VD groups. Additionally, elastin was significantly higher in VD rats than that in normal rats (p < 0.05), with LiESWT-treated rats demonstrating similarly increased levels (Fig. 4c). Col3a exhibited a similar pattern, although the differences did not reach statistical significance (Fig. 4b). Quantitative real-time polymerase chain reaction (PCR) analysis of gene expression in the vaginal tissue. mRNA expression levels of (a) collagen type I alpha 1 (Col1a), (b) collagen type III alpha 1 (Col3a), (c) elastin, (d) alpha-smooth muscle actin (α-SMA), (e) desmin, (f) hypoxia-inducible factor 1 alpha (HIF-1α), (g) transforming growth factor beta 1 (TGF-β1), (h) activating transcription factor 4 (ATF4), (i) CCAAT/enhancer-binding protein homologous protein (CHOP), (j) glucose-regulated protein 78 (GRP78), (k) brain-derived neurotrophic factor (BDNF), (l) vascular endothelial growth factor (VEGF), and (m) glutaminase-1 (GLS-1) in the vaginal tissue. Col1a (a) and elastin (c) expression levels were significantly higher in both vaginal distension (VD) and low-intensity extracorporeal shock wave therapy (LiESWT)-treated VD rats than in the normal group, with no significant difference between VD and LiESWT-treated VD rats. Col3a (b) expression was also significantly higher in the VD group than in the normal group. Data are normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and expressed relative to the normal group. Statistical analysis: Tukey–Kramer honestly significant difference test for parametric data; Steel–Dwass test for nonparametric data. n = 5 per group. Exact p values are indicated in each panel where comparisons reached or approached statistical significance Alpha-smooth muscle actin, desmin, hypoxia-inducible factor-1 alpha, and transforming growth factor-beta 1 exhibited no significant differences among the groups (Fig. 4d–g). Additionally, PERK-related markers (activating transcription factor 4 [ATF4], C/EBP homologous protein [CHOP], and glucose-regulated protein 78 [GRP78]) exhibited no significant differences among the groups (Fig. 4h–j). BDNF, vascular endothelial growth factor alpha, and glutaminase-1 exhibited no significant differences among the groups (Fig. 4k–m). Discussion This study demonstrated that LiESWT restores the passive urethral closure mechanism in a VD rat model of SUI. The baseline urethral pressure and LPP were restored to normal levels. Notably, LPP enhancement persisted after the transection of pelvic, hypogastric, and pudendal nerves. To our knowledge, this is the first report demonstrating that LiESWT-induced functional enhancement persists independently of these neural pathways, indicating that structural restoration of periurethral tissue contributes to the therapeutic effect. At the functional and histological levels, urethral continence during stress events, such as sneezing, depends on both passive and active closure mechanisms [5, 6, 23]. The passive mechanism maintains baseline urethral pressure through sympathetically innervated smooth muscle tone and periurethral tissue support. The passive mechanism is crucial for sustained continence during daily activities, such as standing and walking. The periurethral connective tissue, specifically the anterior vaginal wall, provides a supportive “hammock” that enables effective pressure transmission to the urethra [6]. VD injury disrupts this architecture through mechanical stretching and ischemia, resulting in tissue damage [20, 21]. Our functional results indicate that LiESWT primarily restores this passive mechanism, as evidenced by upregulated Col1a and elastin and a trend toward reduced fibrosis ratio in the vaginal smooth muscle. Unlike the pathological fibrotic response following VD injury, LiESWT facilitates beneficial tissue reorganization that enhances periurethral support. These findings indicated that LiESWT provides early benefit for passive urethral closure within 1 week after treatment. Furthermore, LPP enhancement persisted after additional transection of the hypogastric and pudendal nerves, suggesting that the therapeutic effect is attributable to structural restoration of the periurethral tissue support rather than to the neural tone. At the same functional level, the active mechanism involves rapid contraction of the external urethral sphincter and pelvic floor striated muscle via the somatic nerve [5, 25]. This mechanism is essential for maintaining continence during sudden increases in abdominal pressure, such as sneezing, mediated by Onuf’s nucleus [23]. Additionally, VD causes ischemia and hypoxia in urogenital tissues that may affect neural function [20]. Therefore, this active mechanism is easily impaired by VD injury. Our functional data are consistent with previous reports demonstrating LiESWT efficacy in SUI models [13, 16, 22]. However, the peak pressure response during sneezing remained impaired. Previous studies have reported nerve regeneration and neuromuscular junction formation following LiESWT [13]. The persistent impairment of AUR at this time point indicates that neural regeneration requires longer time frames than structural tissue repair. Long-term observation may reveal enhancement in the active urethral closure mechanism as well. VD-induced ischemia and hypoxia may cause neural damage to the external urethral sphincter [20]. Furthermore, structural and functional recovery of the EUS neuromuscular circuitry after VD remains incomplete even at day 11 post-VD [26], which indicates that the 1-week observation period in the present study was insufficient for full recovery. Additionally, VD-induced mucosal edema may have further impaired pressure transmission to the urethra. At the molecular level, as assessed via RT-qPCR and histological analysis, the expression of Col1a and elastin was significantly higher in VD rats than that in normal controls. This indicates active extracellular matrix remodeling following VD injury. Collagen alterations in pelvic support tissues contribute to pelvic organ dysfunction [7, 8]. Additionally, vaginal trauma alters the urethral connective tissue structure [9]. LiESWT-treated rats maintained similarly increased collagen expression levels, indicating continued matrix synthesis rather than the simple suppression of fibrotic responses. LiESWT modulates macrophage function and facilitates tissue healing [11]. In this study, LiESWT-treated rats histologically exhibited a tendency toward a lower fibrosis ratio than VD controls. This suggests enhanced tissue organization that may improve periurethral support. Furthermore, at the molecular level, western blotting was performed to analyze ER stress signaling for assessing its potential role in LiESWT-induced tissue repair. As described above, LiESWT activates the PERK/ATF4 pathway [18]. However, we did not observe PERK phosphorylation through western blotting 96 h after the final LiESWT session. Additionally, RT-qPCR revealed no significant alterations in PERK-related markers (ATF4, CHOP, and GRP78) or BDNF levels. Prolonged PERK activation and sustained CHOP elevation induce apoptosis and tissue damage rather than facilitate repair [19]. The absence of PERK pathway activation at this time point indicates that LiESWT-induced ER stress response was transient and had already resolved. LiESWT is known to exert its therapeutic effects through multiple mechanisms, including angiogenesis, neuroregeneration, and anti-fibrotic effects [11–16], each potentially operating on different time scales. Future studies examining earlier time points—specifically within the first 6–48 h following LiESWT—may help clarify the temporal dynamics of these molecular pathways. Additionally, mechanosensitive receptors, such as piezo1 [27], and transient receptor potential vanilloid 4 [28] are expressed in urogenital tissues. These may serve as primary sensors of shock wave stimulation, and their assessment can elucidate the precise mechanisms of LiESWT. Overall, these findings support the safety of LiESWT without inducing prolonged ER stress. Clinical studies have demonstrated the efficacy of LiESWT in women with SUI [16, 17]. Our results demonstrated that LiESWT restores baseline urethral pressure and LPP, indicating a clinical benefit for continence during routine daily activities, such as standing and walking. This can reduce anxiety about urinary leakage, thereby enhancing quality of life. The noninvasive nature of LiESWT makes it an attractive option for patients who may not be candidates for surgical intervention. As a noninvasive procedure, LiESWT does not involve surgical incision or reported pain during application. The absence of sustained PERK activation suggests that LiESWT does not induce prolonged ER stress, which is associated with apoptosis and tissue damage. Although these findings highlight the safety of LiESWT, long-term follow-up in clinical trials remains necessary to fully establish its safety. Notably, LiESWT has already been applied in clinical settings for SUI [16, 17]. Because of its effect on passive urethral closure, LiESWT may benefit various patients with SUI, including men with post-prostatectomy incontinence. This study had several limitations. Our urodynamic measurements were performed after pelvic nerve transection. This procedure interrupts autonomic innervation and somatic motor branches that provide supplementary innervation to the pelvic floor striated muscle. Additionally, these branches contribute to AUR during sneezing [25]. Therefore, our results primarily reflect passive urethral closure mechanisms and smooth muscle function. This may partially explain the limited recovery of sneezing-induced contraction pressure after LiESWT. Regarding molecular analysis. The sample sizes for western blotting (n = 3–4 per group) and RT-qPCR (n = 3–5 per group) were small, which may have limited the statistical power. Therefore, markers that did not reach statistical significance may still have undergone biologically meaningful changes, as suggested in previous reports, and null findings should not be interpreted as the absence of effect. Assessment at a single time point (96 h) may not capture the full temporal dynamics of LiESWT-induced molecular alterations. Conclusion In this rat VD model of SUI, LiESWT restored the baseline urethral pressure and LPP to near-normal levels. Histologically, vaginal fibrosis tended to reduce after LiESWT treatment. These functional enhancements persisted after nerve transection, indicating that LiESWT restores passive urethral closure mechanism through effects on the periurethral vaginal tissue. The absence of sustained PERK activation at 96 h after the final LiESWT supports a favorable safety profile. These results support further assessment of LiESWT as a noninvasive treatment for SUI. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 141 KB) Acknowledgements The authors thank Tadanobu Kamijo and Hitoshi Uehara (Department of Systems Physiology) for assistance with experimental preparation, and Masayuki Matsushita (Department of Molecular and Cellular Physiology) for valuable advice. Additionally, we thank DOCTOR’s KITS Co., Ltd. and Medispec for providing the ED-1000 device, Editage (www.editage.jp) for English language editing. Author Contributions T Akimoto: Protocol/project development, Data collection or management, Data analysis, Manuscript writing/editing. A Ashikari: Protocol/project development, Funding acquisition. M Kurobe: Resources, funding acquisition, Manuscript writing/editing. G Takamatsu: Data collection or management, Resources, Manuscript writing/editing. Y Akiyama: Manuscript writing/editing. H Kume: Manuscript writing/editing. M Miyazato: Protocol/project development, Funding acquisition, Manuscript writing/editing. Funding This work was supported by JSPS KAKENHI (grant numbers: 20K11158, 22K11420, 25K14507, and 25K14404). Data Availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Ethics Approval All experimental procedures were performed using a protocol (A2021041) approved by the Institutional Animal Care and Use Committee of the University of the Ryukyus in compliance with the ARRIVE guidelines (https://arriveguidelines.org/). All efforts were made to minimize suffering and the number of rats used in the experiment. Conflicts of Interest None. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary file1 (DOCX 141 KB) Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.